BENGALURU : Glenmark Pharmaceuticals Ltd defended the pricing of its generic version of favipiravir, FabiFlu, on Tuesday, after India's drug regulator had reportedly sent the company a notice on overpricing.Shares of the Mumbai-based company fell as much as 5.8% on Monday after local media reports said the Drug Controller General of India (DCGI) pulled up Glenmark regarding the price of the tablet and other concerns."Compared to other therapies approved for emergency use in COVID-19, FabiFlu is much more economical and an effective treatment option," the company said in a statement to the exchanges.Glenmark also denied making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate COVID-19 patients.FabiFlu's price.